tiprankstipranks
Trending News
More News >
Denali Therapeutics (DE:4DN)
FRANKFURT:4DN
Germany Market

Denali Therapeutics (4DN) Financial Statements

Compare
7 Followers

Denali Therapeutics Financial Overview

Denali Therapeutics's market cap is currently €2.83B. The company's EPS TTM is €-0.6189645691; its P/E ratio is -6.83; Denali Therapeutics is scheduled to report earnings on February 26, 2026, and the estimated EPS forecast is €-0.53. See an overview of income statement, balance sheet, and cash flow financials.
Dec 25Dec 24Dec 23Dec 22Dec 21
Income Statement
Total Revenue$ 0.00$ 0.00$ 330.53M$ 108.46M$ 48.66M
Gross Profit$ 0.00$ 0.00$ 330.53M$ 108.46M$ 48.66M
Operating Income$ -555.34M$ -487.34M$ -196.70M$ -340.74M$ -295.75M
EBITDA$ -555.34M$ -492.89M$ -179.97M$ -330.36M$ -287.16M
Net Income$ -512.54M$ -422.77M$ -145.22M$ -325.99M$ -290.58M
Balance Sheet
Cash & Short-Term Investments$ 867.88M$ 832.33M$ 1.03B$ 1.34B$ 865.41M
Total Assets$ 1.14B$ 1.37B$ 1.15B$ 1.46B$ 1.40B
Total Debt$ 32.74M$ 48.71M$ 52.24M$ 60.35M$ 64.01M
Net Debt$ -172.58M$ -126.25M$ -74.86M$ -157.69M$ -229.47M
Total Liabilities$ 131.09M$ 144.50M$ 122.96M$ 417.81M$ 441.87M
Stockholders' Equity$ 1.01B$ 1.23B$ 1.03B$ 1.04B$ 962.29M
Cash Flow
Free Cash Flow$ -422.10M$ -363.61M$ -370.93M$ -262.55M$ -219.89M
Operating Cash Flow$ -412.60M$ -347.69M$ -357.99M$ -244.72M$ -211.39M
Investing Cash Flow$ 255.28M$ -88.76M$ 249.31M$ -141.39M$ -21.63M
Financing Cash Flow$ 189.22M$ 484.30M$ 17.82M$ 310.67M$ 19.35M
Currency in USD

Denali Therapeutics Earnings and Revenue History

Denali Therapeutics Debt to Assets

Denali Therapeutics Cash Flow

Denali Therapeutics Forecast EPS vs Actual EPS